Benitec Biopharma
Open
$11.12
Prev. Close
$11.13
High
$11.16
Low
$11.09
Market Snapshot
$381.33M
-7.8
-0.01
19
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Recently from Cashu
Benitec Biopharma Advances Gene Therapy for Chronic Hepatitis B and Other Genetic Disorders
Benitec Biopharma Advances Gene Therapy with New Developments Benitec Biopharma, a clinical-stage biotechnology company, focuses on developing innovative therapies using its proprietary gene-silencing…
Benitec Biopharma Appoints Dr. Judith K. Houghton as Chief Scientific Officer
Benitec Biopharma Strengthens Leadership with New Appointment Benitec Biopharma announces the appointment of Dr. Judith K. Houghton as the new Chief Scientific Officer, a strategic move aimed at enhan…
Benitec Biopharma's TT-034 Platform Shows Promise in Gene Therapy for Chronic Diseases
Benitec Biopharma Advances in Gene Therapy Research Benitec Biopharma, a leader in gene therapy, makes significant strides in its research efforts focused on developing innovative treatments for chron…